Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recur… Read more
Evofem Biosciences Inc (EVFM) - Total Assets
Latest total assets as of December 2024: $23.79 Million USD
Based on the latest financial reports, Evofem Biosciences Inc (EVFM) holds total assets worth $23.79 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Evofem Biosciences Inc - Total Assets Trend (2012–2024)
This chart illustrates how Evofem Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Evofem Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Evofem Biosciences Inc's total assets of $23.79 Million consist of 57.2% current assets and 42.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $9.83 Million | 41.3% |
| Inventory | $1.58 Million | 6.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.60 Million | 40.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Evofem Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evofem Biosciences Inc's current assets represent 57.2% of total assets in 2024, a decrease from 98.2% in 2012.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 86.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 41.3% of total assets.
Evofem Biosciences Inc Competitors by Total Assets
Key competitors of Evofem Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Evofem Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Evofem Biosciences Inc generates 0.81x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Evofem Biosciences Inc is currently not profitable relative to its asset base.
Evofem Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.17 | 0.13 | 0.95 |
| Quick Ratio | 0.15 | 0.10 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-66.84 Million | $ -63.25 Million | $ -744.00K |
Evofem Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Evofem Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.37 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 125.4% |
| Total Assets | $23.79 Million |
| Market Capitalization | $1.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Evofem Biosciences Inc's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Evofem Biosciences Inc's assets grew by 125.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Evofem Biosciences Inc (2012–2024)
The table below shows the annual total assets of Evofem Biosciences Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $23.79 Million | +125.40% |
| 2023-12-31 | $10.55 Million | -58.06% |
| 2022-12-31 | $25.16 Million | +30.81% |
| 2021-12-31 | $19.24 Million | -82.51% |
| 2020-12-31 | $109.97 Million | +288.65% |
| 2019-12-31 | $28.30 Million | +605.61% |
| 2018-12-31 | $4.01 Million | -2.64% |
| 2017-12-31 | $4.12 Million | -67.86% |
| 2016-12-31 | $12.82 Million | -68.05% |
| 2015-12-31 | $40.11 Million | -47.84% |
| 2014-12-31 | $76.90 Million | +1597.43% |
| 2013-12-31 | $4.53 Million | -64.67% |
| 2012-12-31 | $12.82 Million | -- |